1. Home
  2. MDWD vs DAVA Comparison

MDWD vs DAVA Comparison

Compare MDWD & DAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MediWound Ltd.

MDWD

MediWound Ltd.

SELL

Current Price

$11.95

Market Cap

162.2M

Sector

Health Care

ML Signal

SELL

Logo Endava plc (each representing one)

DAVA

Endava plc (each representing one)

HOLD

Current Price

$2.04

Market Cap

105.2M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
MDWD
DAVA
Founded
2000
2000
Country
Israel
United Kingdom
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
162.2M
105.2M
IPO Year
2013
2015

Fundamental Metrics

Financial Performance
Metric
MDWD
DAVA
Price
$11.95
$2.04
Analyst Decision
Strong Buy
Hold
Analyst Count
6
8
Target Price
★ $30.67
$5.35
AVG Volume (30 Days)
63.2K
★ 766.7K
Earning Date
11-19-2026
11-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$39.60
N/A
Revenue Next Year
$34.34
$1.12
P/E Ratio
★ N/A
$20.02
Revenue Growth
N/A
N/A
52 Week Low
$11.87
$1.60
52 Week High
$20.03
$9.88

Technical Indicators

Market Signals
Indicator
MDWD
DAVA
Relative Strength Index (RSI) 32.52 42.87
Support Level N/A $1.60
Resistance Level $14.06 $3.06
Average True Range (ATR) 0.42 0.11
MACD -0.15 0.05
Stochastic Oscillator 3.69 85.29

Price Performance

Historical Comparison
MDWD
DAVA

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About DAVA Endava plc (each representing one)

Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.

Share on Social Networks: